Exchange: NASDAQ·Updated 07:58 PM EST
TNXP logo

TNXP Tonix Pharmaceuticals Holding Corp

$2.38
$0.17
(6.67%)
Today
Closed $2.38
$0.0052
(0.22%)
After Hours
Reported EarningsNov 9
Mkt Cap$46.25M
Vol1.26M

About TNXP

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.
36

Bearish Sentiment

How do you feel about TNXP?

JRoc16
$TNXP Scanned through companies last night. Many have the same charts we are seeing with TNXP as of late. Almost identical. Percentages vary due to float sizes, I'm seeing this all over the Market. We have a successful launch. Likely exponential sales through 2027 vs the linear growth we are seeing. Core issue is cashburn/dillution, once we secure a partnership we will eliminate/greatly reduce those concerns. The generic patent challenge is Bullish. We have a drug that others want. Sales continue to grow as stated last earnings call. Recently hired a team member specifically for partnerships. We're fully integrated and have proven we can launch a product successfully, so confident we are building a manufacturing facilty. The Lyme vaccine on deck could be a huge player, label expansion on an already great drug, approaching a 100M run rate in its 1st year of launch is a success. Seth will always keep 3-4 quarters of cash everyone knows this. I was anticipating 20M os shares this Q3.
17
JamesDecap
$TNXP market cap shows you how massively oversold this is, tonmya sales + entire pipline being priced at $0, while cash in bank on 50% discount. absolutely crazy. holding strong + long.
2
9
Akabos77
$TNXP likely bottomed around $2.8 Now, what happens next, depends on us, retail. Institutional money is here. They are not gonna sell (much) more at these levels. ATM is likely over. If we don't sell, it goes to 4.5-5 within a couple of weeks. Not expecting $8 or $14 anytime soon. But $4.5-5 is very likely even prior to any major news.
3
6
JamesDecap
$TNXP people posting their conspiracy level beefs with Seth are hilarious. we know you are shorting it. no one could have such an inflated ego to believe a CEO would reply to their fake emails they are sending. Tonmya on track for >$2M weekly sales & growing with 150 reps in full swing. I can wait for growth & inevitable rerating up!
3
6
JustAguysOpinion
$TNXP good lord whole chat shorts a d fake bulls 😆 🤣 I wasn't too thrilled about the extra cost during earnings but drug is trucking along and the call was good. Tonmya still growing weekly. Even on the call they mentioned how it ramped after the deployment of extra sales force in September. Q4 brings the fruits of the extra 21m. The goodmorning segment def reached people. People are refilling more. Providers according to the call say it's been life-changing. Small bio launching on its own isn't easy but tonix doing great. I have no beef with Seth either but im also not a short wanting to mess with company. Tonmya won't be a blockbuster till they get the other conditions approved. Tho it should hit 700-800 on it's own in my opinion as things are going. Tonmya climbs and competitors went stale. I can wait
15
StockJayC
$TNXP TONMYA launched on 17 November 2025. We're less than one year into commercialisation, and Q3 delivered $17.2M. Annualised, that's a ~$69M revenue run rate, with TONMYA contributing ~$60M. Now consider the valuation potential. Pharmaceutical businesses can attract revenue multiples depending on growth, market opportunity, margins and strategic value. Even a hypothetical 4x multiple on the current annualised revenue implies ~$276M in enterprise value, before considering Tonix's pipeline and cash. And here's what makes the trajectory interesting: • Only ~53% of US covered lives currently reached. • 150 sales representatives now deployed. • No established widespread preferred formulary positioning yet. • Public-facing marketing is now ramping up, including Good Morning America. • Q3 prescriptions +28%, new prescriptions +17% and refills +56%. TONMYA is the first new FDA-approved fibromyalgia treatment in over 15 years. YES WE'RE ALL DOWN BUT KEEP HOPES HIGH
1
11
h8ster
$TNXP So many people here still don't get it or understand whats been happening in the spec bio sector since last august. How people can be so disconnected from the general market, current economic conditions, not knowing whats happening sector wide and are still flat out surprised with the current statistically historic collapse of the spec bio sector is wild to me. People here actually think it's just TXNP thats fallen. Just wild.
13
cdat
$TNXP Can we get a class-action suit against this scam company . Being deceptive is a starter.
1
10
h8ster
$TNXP We're witnessing f the largest institutional capital withdrawals and degrossing events in speculative biotech history, beginning in late August. I've traded biotech through the 2008–09 financial crisis, 2011–12 debt crisis, 2015–16 biotech collapse, COVID, and the brutal 2022 inflation selloff. I've never seen anything quite like this. The biggest difference today? AI driven algo trading dominates institutional markets. No human emotion. No patience. When risk models demand reduced exposure, TNXP's fundamentals become irrelevant. Just relentless selling. Now add the AI/tech collapse to an already devastated biotech sector. It's a pressure cooker boiling over. Excessive leverage, margin calls, forced liquidations, and panic selling feed on themselves. The babies aren't just being thrown out with the bathwater. They're being flushed down the drain! These cycles eventually reverse. The challenge is surviving, identifying genuine value, and having the patience to wait for recovery.
10
StockJayC
$TNXP if this drops to sub $2 and I see no buybacks… I’m flying to the states and doing a Q&A with him!!
11
h8ster
$TNXP What makes this quiet, Bank vs Spec Bio war, even worse than 2022, when inflation was worse, rates were worse, yields were worse, is that now, AI is in control of nearly all the liquidity across the sector. Multi-million dollar AI trading programs/algos, built by the big banks, are wreaking havoc across the entire niche sector. No emotion. Complete mayhem. Think about this. TNXP reported $162.8M in cash as of 9/30 and generated $17.2M in Q3 product revs....an annualized run rate of nearly $69M . With TONMYA sales growing 37% sequentially, TNXP has a realistic opportunity to approach a $100M annual rev run rate as commercialization progresses. Yes, expenses and cash burn remain large, and future financing is a concern. But for TNXP, with an FDA approved, revenue generating product, growing sales, and a substantial development pipeline to carry a market cap of just $63 million...less than 40% of its last reported cash balance....is an extraordinary valuation disconnect.
13
Businesspro
$TNXP What happened here? The company beats earnings on revenue CEO buys more shares at $4 Rated a Strong buy Analysts price target 🎯 $31 Analysts potential upside is 875%! However the stock continues to crash another 16% just today Scam market working it’s hardest it ever has Everything is backwards with no logic Don’t take this market too serious Scam mode has been activated since October 1st
1
10
JRoc16
$TNXP Got some dry powder ready to deploy next week if these prices choose to hang around!
7
brj1323
$TNXP oversold much 👀 got my eye on her for technical reversal coming soon. Looking for a bottom first. Volume increasing
11
StocketShip
$TNXP If Tonmya is doing so great then maybe Tonix would be alright with giving us a spreadsheet of all the scripts?
8
StockJayC
$TNXP Can I also check, why have we not utilized social media ads on facebook? Demographic of facebook is the perfect crowd, middle aged women & moms who post about their kids? Large number of support groups within Facebook and highest activity? Send me the offer letter seth, I'll take over as CEO and CMO whilst working full-time
9
stefano62
$TNXP this i real garage. I bought It Just before approval 1 year ago and now I am loosing 94%!!!!
8
ronft
$TNXP Large volumes of shares are still changing hands, and there is no sign of a trend reversal in the near term—not even from a technical perspective. Nevertheless, there is hope for a better future and a potential reversal of the trend. Wishing everyone a good and blessed week.
1
7
HarmonyPioneer67
$TNXP Tailwinds for 2027: • Medicare coverage: A managed Medicare GPO coverage agreement takes effect January 1, 2027. That's significant for a fibromyalgia drug, since many patients are older. • More sales reps: Tonix said it would grow its sales force from 100 to 150 people by September 2026. The full-year effect of that shows up in 2027. • Room to grow: About 10 million US adults have fibromyalgia, and management is targeting the 3 million already diagnosed and treated. The roughly 16,000 Q3 prescriptions are a small slice of that.
9
Manu56
$TNXP Tonix is burning approximately $3.2m a week. Why is management continuing to spend so heavily on research when TONMYA has yet to achieve adequate market penetration? The priority should surely be maximising commercial sales, building revenue and reducing the cash burn before committing even more shareholder money to research. Shareholders must stop accepting silence and demand accountability. We need to make our voices heard collectively. Demand a clear breakdown of expenditure, a credible plan to cut the cash burn, measurable TONMYA sales targets and a firm strategy to reduce further dilution. Contact Investor Relations, challenge management directly and insist that the Board addresses these concerns. This is our investment and our money. Management is accountable to its shareholders. We deserve answers, financial discipline and action — not another round of optimistic promises while shareholder value is diluted.
8

Advertisement|Remove ads.